Jones Financial Companies
GTBP icon

Jones Financial Companies’s GT Biopharma GTBP Stock Holding History

Jones Financial Companies’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$645 Buy
+1,500
New +$608 ﹤0.01% 4705
2025
Q4 		– Sell
-300
Closed -$230 – 4487
2025
Q3 		$230 Hold
300
– – ﹤0.01% 4117
2025
Q2 		$1.06K Buy
+300
New +$775 ﹤0.01% 3644

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

Jones Financial Companies's GTBP Position: Q2 2026 in Review

Jones Financial Companies opened a new position in GT Biopharma (GTBP) in Q2 2026: 1,500 shares worth $645. The stake represents ﹤0.01% of the portfolio and ranks #4705 among its holdings. This is a return to the name: Jones Financial Companies previously reported a position in GTBP as recently as Q3 2025.

Jones Financial Companies first reported a position in GTBP in Q2 2025 and has held it in 3 quarters since. The position peaked at $1.06K in Q2 2025. 59 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • Jones Financial Companies held 1,500 shares of GT Biopharma worth $645 as of Q2 2026.
  • GT Biopharma was a new Jones Financial Companies position in Q2 2026.
  • GT Biopharma made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #4705 holding.
  • Jones Financial Companies first reported a position in GT Biopharma in Q2 2025 and has held it in 3 quarters since.
  • Jones Financial Companies's GT Biopharma position peaked at $1.06K in Q2 2025.
  • 59 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.